[1] TORRES HA, HACHEM RY, CHEMALY RF, et al.Posaconazole: a broad-spectrum triazole antifungal[J]. Lancet Infect Dis, 2005, 5(12): 775-785. [2] TACKE D, KOEHLER P, MARKIEFKA B, et al.Our 2014 approachto mucormycosis[J]. Mycoses, 2014, 57(9): 519-524. [3] CORNELY OA, ARIKAN-AKDAGLI S, DANNAOUI E, et al.ESCMID and ECMM joint clinical guide-lines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014, 20(3): 5-26. [4] RILEY TT, MUZNY CA, SWIATLO E, et al.Breaking the mold: a review of mucormycosis and current pharmacological treatment options[J]. Ann Pharmacother, 2016, 50(9): 747-757. [5] VAZQUEZ JA, SKIEST DJ, NIETO L, et al.A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS[J]. Clin Infect Dis, 2006, 42(8): 1179-1186. [6] CORNELY OA, MAERTENS J, WINSTON DJ, et al.Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia[J]. N Engl J Med, 2007, 356(4): 348-359. [7] ULLMANN AJ, LIPTON JH, VESOLE DH, et al.Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J]. N Engl J Med, 2007, 356(4): 335-347. [8] VISHNUBHOTLA P, IBRAHIM RB, ABIDI MH, et al.Fever and eosinophilia associated with voriconazole[J]. Ann Pharmacother, 2004, 38(5): 900-901. [9] GRZEGORCZYK B, MURATA Y.Peripheral eosinophilia and eosinophilic colitis during long-term azole therapy for pulmonary aspergillosis[J]. JMM Case Rep, 2014, 1(4): e004135. [10] MAHER A, RAE-KIRAN J, TERENCE W, et al.Marked peripheral eosinophilia due to prolonged administration of posaconazole[J]. JMM Case Rep, 2017, 4(6): e005100. [11] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. [12] NARANJO, CLAUDIO A, SHEAR, et al. Advances in the diagnosis of adverse drug reactions[J]. Journal of Clinical Pharmacology, 1992, 329(10): 897-904. [13] LI X, CHU YQ.A case skin rash eosinophilia caused by tigecycline[J]. Clinical Medicaion Journal(临床药物治疗杂志), 2019, 17(11): 90-92. [14] CUI HX, YU SW.Retrospective analysis of 125 cases of adverse drug reactions induced by tigecycline[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(8): 489-492. [15] WALSH TJ, ANAISSIE EJ, DENNING DW, et al.Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360. [16] FREIFELD AG, BOW EJ, SEPKOWITZ KA, et al.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2011, 52(4): 56-93. [17] STEVENS DL, BISNO AL, CHAMBERS HF, et al.Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2014, 59(2): 10-52. [18] PERFECT JR, DISMUKES WE, DROMER F, et al.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America[J]. Clin Infect Dis, 2010, 50(3): 291-322. |